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Wij bevinden ons aan het begin van een nieuw medisch tijdperk waar 
kanker doodsoorzaak nummer één wordt. De strijd tegen kanker 
wordt gevoerd met een snel uitbreidend arsenaal van middelen, maar 
vooruitgang staat of valt met het beter begrijpen van de ziekte. Ons 
begrip wordt gedreven door het ontwikkelen van nieuwe manieren om 
naar de ziekte te kijken; nieuwe ‘looking glasses’ zoals DNA sequencing 
technologie. Maar darmkanker leidt tot zulke chaotische veranderingen 
op moleculair niveau dat eenvoudige invalshoeken, zoals het bestuderen 
van erfelijke vormen van kanker, vaak meer bruikbare informatie leveren. 
Met vooruitgang in moleculair darmkankeronderzoek dreigt de kloof 
tussen de artsen en de onderzoekers zo groot te worden dat ze elkaar niet 
meer kunnen begrijpen. In het aanbrekende moleculaire tijdperk zullen 
clinici met moleculaire kennis steeds belangrijker zijn om deze kloof te 
overbruggen. De hoop blijft dat er, met meer kennis door ontwikkelingen 
van nieuwe moleculaire en endoscopische ‘looking glasses’, een tijd 
aanbreekt waar het monster darmkanker getemd zal worden.
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’Twas brillig, and the slithy toves
Did gyre and gimble in the wabe:
All mimsy were the borogoves,
And the mome raths outgrabe.
“Beware the Jabberwock, my son!
The jaws that bite, the claws that catch!
Beware the Jubjub bird, and shun
The frumious Bandersnatch!”
He took his vorpal sword in hand;
Long time the manxome foe he sought—
So rested he by the Tumtum tree
And stood awhile in thought.
And, as in uffish thought he stood,
The Jabberwock, with eyes of flame,
Came whiffling through the tulgey wood,
And burbled as it came!
One, two! One, two! And through and through
The vorpal blade went snicker-snack!
He left it dead, and with its head
He went galumphing back.
“And hast thou slain the Jabberwock?
Come to my arms, my beamish boy!
O frabjous day! Callooh! Callay!”
He chortled in his joy.
’Twas brillig, and the slithy toves
Did gyre and gimble in the wabe:
All mimsy were the borogoves,
And the mome raths outgrabe.
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Mijnheer de Rector Magnificus, zeer gewaardeerde toehoorders, 
honoured guests, ladies and gentlemen, 
some of you may now be wondering whether you haven’t taken 
a wrong turn and ended up in a poetry seminar, others of you 
will be wondering, much like Alice in Lewis Carrol’s ‘Through 
the looking glass’ when she found and read this poem, “What is 
this nonsense?” 
Monster
Jabberwocky is one of the most famous nonsense poems in the 
English language and forms part of the fantastical world that 
Alice, following on from her adventures in wonderland, finds 
on stepping through a looking glass. Upon finding the poem, 
Alice realises that she needs the looking glass (here a mirror) 
to read it at all as it is written in mirror-writing, and even then 
it appears to be largely nonsense. Later in the book she meets 
Humpty Dumpty who tries to explain the poem to her. So 
sitting up on my wall here and without falling off I will try to 
explain things to you, while taking you on a short trip through 
the looking glass into the world of colon cancer.
The poem is clearly about a fearsome monster, finding it 
and ultimately decapitating it. Cancer is indeed a monstrous 
disease and the disease that everyone fears. Hippocrates 
seems to have started the monster metaphor referring to the 
disease as ‘karkinos’, Greek for crab, perhaps referring to the 
hard round shell and sharp claw like projections. In Greek 
mythology Karkinos, a monstrous giant crab, was sent by 
Hera to distract Heracles from killing the Hydra. One swift 
kick from Heracles cracked the shell and killed Karkinos. The 
Roman physician Celcus then translated the Greek Karkinos 
to the Latin ‘Cancer’. So Cancer is a monster that grabs you in 
its claws while you least expect it. Colon cancer is particularly 
scary in this respect because it creeps up so unexpectedly, 
growing unseen, without symptoms, without obvious risk 
factors and it is frequently fatal. Cancer is not only monstrous 
for the individual but after a century in which we conquered 
infectious disease followed by an era where health was 
dominated by heart disease we are now moving into a new 
era where cancer will be the worlds greatest threat to health.1 
Among the various different types of cancer, colon cancer is 
the second biggest killer after lung cancer, with 1 in 20 of us 
developing the disease within our lifetime.
Cancer metaphors
Metaphors have a long tradition in cancer. In 1971 President 
Nixon famously declared war on cancer, thereby unwittingly 
setting a dangerous precedent for US presidents to declare 
war on nebulous adversaries! No other disease attracts the 
use of violent military metaphors in the way that cancer 
does. Cancer is described as an “evil, invincible predator” 
with “cells that invade the body”. Patients are “bombarded” 
with radiation, and receive chemotherapy that is portrayed as 
“chemical warfare that destroys to save”. The discussion about 
the impact of these metaphors is still lively with breast cancer 
sufferer Susan Sontag arguing that their use shames patients 
who are not only ill but then implicitly ‘lose’ or ‘give up’ if 
the disease progresses. However, metaphors are a colourful 
way to conceptualise disease so I intend to continue in this 
tradition. How can we find and defeat this Jabberwock that is 
colon cancer? Accepted wisdom would suggest that you should 
know your enemy, requiring a fair amount of ‘uffish’ thought. 
You’ve also got to find the ‘manxome’ foe in the ‘tulgy’ wood. 
You’ve got to be able to recognise the enemy; are you sure it’s 
the Jabberwock you’re looking for and not the Jubjub bird or 
the Bandersnatch? And if other subtler approaches fail you can 
always take your vorpal sword and lop off its head!
Understanding the enemy
There are various levels at which you can try and understand 
colon cancer in order to prevent and treat it and both in my 
clinical practice and my research I have been active in several 
of these areas. Understanding begins with observation and in 




However, early observation of cancer with the naked eye even 
after dissection of the human body became acceptable, failed 
to increase understanding appreciably. Cancer remained a 
disease caused by Gods or bodily humors from the time of the 
Ancient Egyptians right up the 19th century. More successful 
attempts at deciphering the cancer riddle required a looking 
glass, not a mirror as in Alice’s case to decipher Jabberwocky, 
but the microscope. The microscope enabled the German 
pathologist Johannes Muller to develop his Blastema theory, 
that cancer was made up of cells and not caused by lymph or 
humors. Even today when the last 2 decades have seen more 
advancement in the understanding of cancer than the rest 
of history put together, observations through a simple light 
microscope continue to be the mainstay of diagnosis and 
are often the starting point for revolutionary new theories in 
cancer biology. A recent example of this is the realisation of 
the importance of the non-cancerous stroma support cells in 
colon cancer. Estimation of the degree of stromal reaction at 
the site of invasion of colon cancers by simple microscopic 
observation has revealed that cancers with more stromal 
reaction have a worse prognosis.2 Subsequently reanalysis of 
global gene expression studies in colon cancer have shown 
that the signatures defining a particularly aggressive colon 
cancer subtype all arise from the non-cancerous support 
cells.3 This together with mouse models where manipulations 
of the support cells both initiate and potentiate cancer 
growth, have lead to a resurgence of interest in the cancer 
microenvironment.
Looking glass 2.0
So advances in molecular biology have also enabled us to 
look at cancer in new ways, moving on from physical to 
molecular methods. While the microscope revealed the chaotic 
nonsense that is cancer as being a cellular phenomenon, 
analysis of DNA revealed it as a genetic disease, and analysis 
of genes and their function revealed it to be a disease of faulty 
molecular signalling with gradual corruption of the normal 
checks and balances controlling individual cell behaviour in a 
multicellular organ such as the bowel. So our understanding 
of cancer has been driven in part by the development of new 
tools with which to look at it: In essence, new looking glasses. 
Unfortunately, as Alice found, being able to read the poem is 
only the first step in understanding it. As cancer progresses, 
its growth becomes increasingly chaotic going into and 
through adjacent tissues and organs and eventually spreading 
to distant parts of the body as metastases. In the same way 
the cancer genome, its DNA, becomes increasingly chaotic 
as layer upon layer of ingenious mechanisms to detect and 
repair DNA damage are corrupted. As we develop new ways 
of looking at cancer in a global unbiased fashion and delve 
deeper by developing new ever more complex technologies, 
each time we are faced with the problem of how to interpret 
what we find. The so-called ‘omics’ technologies such as 
genomics, transcriptomics and proteomics have captured the 
public imagination. The hope is that this sort of ‘Big Science’ 
will combine the mysterious magic of ‘big data’ with massive 
computer power and somehow, almost without the need for 
a question, will reveal answers that careful hypothesis driven, 
small scale research have failed to reveal. I think this optimism, 
certainly in colon cancer, is unfounded. We may be able to 
accurately say which of the 25,000 genes is mutated and at 
what frequency; which genes are silenced through methylation 
and to what degree; which genes are deleted or amplified, 
which genes are expressed at RNA level and which proteins, 
short hairpin RNAs and other non-coding RNAs result. But 
can we then calculate the integrated effect of these changes 
on the various cellular signalling pathways that control cell 
function? Trying to decipher the chaos remains a gargantuan 
task. You could liken it to working out the root cause of an 
air crash while only having access the resulting wreckage. Just 
because the wing of the plane is broken off in the wreckage 
does not mean this was the cause of the crash. Colon cancer, 
through this sort of looking glass is for a large part rubbish 
arising from collateral damage whose decryption is as 
subjective as interpreting Jabberwocky. 
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Inherited cancer syndromes
Luckily there are lines of evidence for molecular research into 
colon cancer that provide simpler more focussed starting 
points, a bit like finding the black box flight recorder after the 
air crash. Colon cancer has a strong hereditary element. As 
far back as 1895 families have been identified where multiple 
family members develop colon cancer. Subsequently the 
underlying genetic mutations and molecular pathways have 
been identified. Inherited cancer syndromes are caused by 
inherited mutations. Families with the syndrome include those 
with the disease and those without. By comparing the DNA of 
those with to those without, the segment of DNA responsible 
can relatively easily be found and genes within these segments 
checked for mutations. In this way cancers arising in a family 
can be seen to be due to a mutation in one gene, the air 
crash can be attributed to one faulty warning light. However, 
inherited colon cancer is only responsible for a tiny proportion 
of all colon cancers. The importance of these rare cancers is 
that they allow us to identify genes in which mutations are 
the root cause of colon cancer and not just the result of the 
massive collateral damage caused during disease progression. 
When we take this knowledge back to the non-inherited 
majority of colon cancers, we often find the same genes are 
mutated or other genes within the same signalling pathway, 
leading to the same net result. It is one of these pathways, 
identified initially in families suffering from Juvenile Polyposis 
syndrome, which I have been specifically investigating now for 
15 years.4 The Bone Morphogenetic Protein, or BMP pathway, 
gets its name from where it was initially discovered, in bone. 
But it does much more than influence bone growth leading 
some to suggest it be rechristened the Body Morphogenetic 
Protein pathway. Now on the surface it may seem that studying 
one signalling pathway in one disease must be pretty limited, 
ridiculously specialised. But the fascination of cancer biology 
is the insights that disease gives into the intricate workings of 
the building blocks of life itself. While early anatomists like 
Boerhaave wondered at the grotesque foetal malformations 
leading to children with one central eye like the Cyclops, 
too many fingers or fused legs like a mermaid, we now see 
with the same fascination similar monstrous deformities 
in a microcosm. We see how cellular organisation of the 
microscopic fingers or villi of the intestine can be corrupted by 
alterations in the signals cells use to orientate themselves in 3 
dimensions, so-called morphogens like BMP. Often it is even 
the same signals that perform similar organisational functions 
in both the embryo and the intestinal villi. So while Hedgehog 
pathway disruption leads to one-eyed Cyclops babies, it also 
leads to mutant intestinal villi. Likewise changes in levels of 
BMPs lead to children born with too many fingers and, in the 
microcosm of the intestinal villus, to cells mistakenly thinking 
that they are at the bottom of the villus when they are actually 
in the middle, and then starting to make new mutant fingers 
half way up and at right angles to an existing finger. In this 
way we can begin to explain the weird patterns of growth that 
the pathologists observe in colon polyps down the microscope 
and use to classify them. So together with many other research 
groups worldwide I have been involved in trying to establish 
exactly how the inherited changes leading to colon cancer do 
their damage.5 It’s the same sort of fascination that makes air 
crash investigations popular television viewing. Can we trace 
and explain all of the steps leading back from the disaster to 
the one faulty screw?
Fundamental research under pressure
The paradox with fundamental molecular research is that, 
despite the fact that all the new cancer therapies stem from 
better molecular understanding of cancer, there is a growing 
disillusionment with it and especially the time frame from new 
molecular understanding to translation into a new cure. It is 
increasingly difficult to secure funding for molecular research 
with funding bodies putting more emphasis on research 
where the implications for patients are more immediately 
apparent, perhaps influenced by the trend to involve patient 
groups in funding decisions. As cancer research continues 
to split into an ever expanding number of disciplines from 
psychological impact, to nutrition, advances in surgery, 
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endoscopy, imaging, quality of life, pharmacology, patient 
value and systems biology, competition for limited research 
resources is increasingly determined by short term societal 
impact. To my mind we have embarked on an irrevocable 
course; the desire to understand the human body and disease 
at the most fundamental level possible and if initial optimism 
as to the time this would take was unfounded, we should 
only redouble our efforts. We need more clinician scientists 
involved in basic research and careful nurturing of this career 
path. When I started my PhD it was clear to me that clinicians 
of the future should be schooled in basic science and that 
real research involved active participation in the molecular 
revolution. I’m not sure that this view is still dominant among 
physicians in training today. We have to be wary of a dumbing 
down of medicine with original thinking making way for 
slavish guideline following and where basic research is left to 
biologists.
To return to our military campaign against the Jabberwock; 
while attempts to understand the monster at a nuts and bolts 
level, at the level of DNA and molecular pathways, are leading 
to an increasing armoury with which to battle advanced 
colon cancer, the number of patients ultimately dying from 
the disease has not changed dramatically. How else can we 
approach it?
Prevention
One attractive way is to try and prevent the disease in the 
first place. How and where do Jabberwocks breed and can 
we destroy their breeding grounds? Risk factors for colon 
cancer have been identified from large epidemiological 
studies. Smoking, obesity, and a Western lifestyle are the most 
important modifiable risk factors in which diet and limited 
physical activity are the most important aspects of the Western 
lifestyle that lead to an increased risk. Vast amounts of research 
have been performed to try and identify the specific dangerous 
components of the Western diet. Red meat, burnt red meat, 
processed meats, saturated fats, cholesterol and fibre have all 
been implicated but perhaps the strongest evidence is for a 
general role for energy imbalance, too many calories being 
consumed and too few expended. I have been involved with 
trying to identify the molecular mechanisms for some of these 
risk factors. One interesting observation has been that the 
obesity hormone Leptin can stimulate colon cancer cell growth 
and thus is likely to be one of the factors coupling obesity with 
a higher risk of colon cancer.6
A further long recognised factor protecting against colon 
cancer is the regular use of certain drugs, particularly Aspirin 
and cholesterol lowering drugs. These observations have 
spawned a whole new field aiming to prevent colon cancer 
with drugs, so called chemoprevention. What the field makes 
painfully clear is that one of the big challenges is performing 
the extremely large and long running trials needed to prove the 
effectiveness of this approach. This is especially true for older 
cheaper drugs such as Aspirin where there is little incentive for 
big pharmaceutical companies to fund such trials. In fact there 
are good reasons why they should be extremely circumspect 
with regard to such trials. In 2004 Merck had to withdraw the 
anti-inflammatory drug Vioxx from the market after results 
from a large chemoprevention study in colon cancer clearly 
confirmed an increased risk of strokes and heart attacks.7 
Vioxx had generated 2.5 billion dollars in sales revenue in 
the previous year and had been used by 80 million patients 
worldwide. Trying to expand the indications for the drug to 
include the chemoprevention of colon cancer, which would 
have likely been a minor indication compared to its use as a 
painkiller, proved fatal. Subsequently it has become clear that 
many similar painkillers, for example Ibuprofen, have a similar 
risk profile, also increasing the chance of stokes and heart 
attacks. However, the drug remains withdrawn and Merck has 
had to pay more than 5 billion dollars in court settlements. The 
dramatic negative consequences of performing the extremely 
expensive, large, long-term trials needed to establish a drug as 
a chemopreventive agent with the uncertainty that they will 
be widely used for this purpose has major implications for 
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this field. My particular area of interest in chemoprevention 
has been the cholesterol lowering drugs, the statins. This 
was sparked by the results of a large pharmacological screen 
for drugs that influenced the Bone Morphogenetic Protein 
pathway. This screen showed that of the 30,000 drugs tested, 
the 2 most effective in stimulating the BMP pathway were 2 
Statins. Subsequently we have gone on to show that Statins can 
kill colon cancer cells by stimulating the BMP pathway.8 Our 
most recent research, together with the department of surgery 
in the LUMC, has shown that continuing to use Statins after 
an operation for colon cancer strongly reduces the chance of 
dying overall.
Holistic prevention
Interestingly one of the criticisms of this study was; could we 
be sure that the statins weren’t just reducing the chances of 
dying from heart disease? The implication being that if that 
was the case then the result was irrelevant. Well from other 
similar studies we know that about 85% of the deaths in 
patients operated on for colon cancer are due to the cancer 
itself. However, it does reveal a very blinkered, monomaniacal 
approach to disease that is very prevalent. Colon cancer 
researchers are only interested in deaths from colon cancer 
and strategies to prevent or intervene in colon cancer rarely 
take other concurrent diseases into consideration. However for 
the patient a more holistic approach makes much more sense. 
How you die is of less importance than whether you are alive 
or dead. Colon cancer shares many of the same risk factors as 
cardiovascular disease and for this reason many patients suffer 
from both at the same time.9 Currently health care focuses on 
one or the other of these problems entirely separately. So major 
investments are made in one area, a bypass or coronary stent, 
without a simple screen for colon cancer and likewise colon 
cancer screening programs pay no attention to concomitant 
cardiovascular disease. A more holistic approach specifically 
in this area would perhaps address the anomaly that despite 
the fact that we know screening for colon cancer is effective 
at reducing deaths from colon cancer, they currently have no 
effect on mortality overall.10 The implication is that we can 
save patients from their colon cancer but they nevertheless die 
at approximately the same time from a stroke or a heart attack.
I think that this can potentially be improved by combining 
screening for colon cancer with screening for cardiovascular 
disease. This may mean that the choice as to which screening 
technique to use in the future should take into account the 
possibility of integrating it with cardiovascular screening. 
For instance testing for both from the same blood sample 
or simultaneous colon and coronary artery CT scanning. I 
also think treatment would benefit from more emphasis on 
mortality overall. Our studies would suggest that a simple 
low risk combination of Aspirin and a statin especially in the 
ever larger group of colon cancer patients of advanced age, 
poor health from other diseases or with a low a risk of the 
cancer recurring, could improve overall mortality. However, 
this unglamorous approach still requires large randomised 
controlled trials to prove it beyond doubt and it is questionable 
whether such trials will attract sufficient funding to be able to 
perform them.
So far I have covered relatively subtle ploys to address the 
threat of colon cancer but as we have heard in the poem, the 
traditional and still most common approach to the Jabberwock 
is distinctly less subtle and in essence boils down to variations 
on the theme of ‘taking your vorpal sword in hand’. However, 
before the exciting and fulfilling ‘snicker-snack’ and proudly 
galumphing back with its head the gastroenterologist hero of 
this story has to find the enemy. As endoscopists we’re most 
keen to find fledgling Jabberwocks before they become fully 
grown monsters; colon polyps.
Finding the enemy: looking glass III
To do this we make use of a particular type of looking glass, a 
flexible endoscope. When I began in endoscopy there was little 
or no consideration given to finding colon cancer or polyps. 
We were content to have reached the end of the colon at all 
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and cancers or polyps were either obvious in which case they 
jumped out and hit you in the face, or they were not there. 
The alternative, a barium enema was even worse so we could 
perhaps be forgiven for our complacency. It was the Japanese 
who first raised awareness of the existence of what we now 
call non-polypoid polyps, a wonderful Oxymoron that could 
be straight out of a nonsense poem. So suddenly some polyps 
weren’t polyps at all. Worse was to follow as after thinking that 
we could tell the harmless polyps from the dangerous ones, 
it suddenly transpired that we’d got it the wrong way round. 
Polyps previously classified as hyperplastic and therefore 
irrelevant and innocuous, requiring no treatment and no 
follow up, were suddenly reclassified as sessile serrated polyps. 
Worse still, they were frequently flat, often not recognised 
at colonoscopy and were probably more aggressive than 
classic adenomatous polypoid polyps.11 Now we not only 
had to find the Jabberwock but also the Jubjub bird and the 
Bandersnatch. Suddenly colonoscopy couldn’t be trusted any 
more. Frightening figures for the percentage of polyps missed 
at colonoscopy12 and the chance of developing cancer after a 
colonoscopy13 confirmed that finding and recognising cancer 
precursors by looking with normal white light was far less 
accurate than we had thought. Ironically increased awareness 
of the fallibility and potential inaccuracy of colonoscopy 
occurred at the same time as dramatic improvements in both 
equipment and its technical performance. As any of you who 
have made videos with successive generations of smartphones 
will appreciate, the latest generation colonoscopes have 
incomparably better resolution than their predecessors. 
Training in colonoscopy has also improved dramatically 
including, for example, more use of simulators, a bit like 
training pilots with flight simulators. The problem is that 
recognition of polyps at standard colonoscopy still relies on 
them protruding from the colon wall and having a different 
colour than the surrounding normal colon; in other words 
their physical characteristics. Flat polyps show neither of these 
discriminating attributes. One solution has been to spray a 
blue dye onto the colon wall and indeed a large Dutch trial of 
this technique in patients with inherited colon cancer is nearly 
complete. This should make it clear whether it has added 
value compared to standard white light endoscopy. It is not 
the most user friendly of techniques requiring quite laborious 
spraying of the dye onto all areas of the colon wall. This topical 
application of dye to the colon is fraught with difficulty. Deep 
folds and sharply angulated segments of the colon, residual 
faeces and adherent mucus all severely hinder advanced 
imaging techniques that rely on topical application of a dye. 
A simpler technique uses blue light instead of white to help 
detect polyps. This can be performed at the touch of a button 
but blue light mainly helps in the classification of polyps close 
up. Could fluorescent light help to identify polyps? Initial work 
in this area made use of autofluorescence and at wavelengths at 
which faeces also fluoresces. Autofluorescence, or the natural 
fluorescence of the colon, can be assessed with the touch of a 
button on the endoscope but in trials in clinical practice it has 
proved of little added value in finding polyps.
Looking glass 4
Perhaps what is needed is a fundamentally new type of 
looking glass for use in the colon, again moving on from 
physical to molecular. Wouldn’t it be nice if we could tag 
polyps with a fluorescent marker at a wavelength where there 
is no background in the colon so that polyps would fluoresce 
and shine out clearly like light bulbs from the normal colon? 
And, of course, we don’t want any of that messy dye spraying 
so it has to be given intravenously and, of course, it has to 
be completely safe. Sounds like science fiction! But recently 
we have published our first experiences with a prototype 
near-infrared colonoscope and an intravenously delivered 
fluorescent-labelled probe that specifically sticks to polyps. 
With this system polyps glow bright green in the dark allowing 
us to detect a number of flat polyps that were invisible with 
normal white light colonoscopy.14 We’ve given the Jabberwock 
eyes of flame! This raises the exciting prospect of molecular 
imaging opening the way for much more accurate detection of 
not only cancer but also, for example, nerves. This will allow 

Colon cancer through the looking glass
surgeons and endoscopists to see things in real time that we 
cannot see with normal light.15
Vorpal sword
So now after a long search in the ‘tulgy’ wood we’ve found 
the ‘manxome’ foe. The real thrill of endoscopy came with 
the development of weaponry to attack the monster. This 
began simply. The classical Jabberwock polyp with a bulbous 
head and a long neck is relatively easy prey. It is quite simple 
to pass a wire loop over the head of the polyp and ‘snicker-
snack’, or in this case a few beeps from the electrosurgical 
unit, and you’re galumphing back with its head. Things 
become trickier when the polyp has no neck and is too big 
to fit into the wire snare in one piece. Large numbers of this 
sort of polyp are still referred to the surgeons for removal 
of a segment of colon containing the polyp but increasingly 
they can also be removed endoscopically. We are approaching 
the point where it is technically possible to remove all polyps 
endoscopically wherever they are in the colon. Endoscopic 
removal can usually be done on an outpatient basis and 
complications especially when compared to the short and long 
term complications of the alternative surgical treatment, are 
infrequent and minor.16 Endoscopic therapy is the ultimate in 
minimally invasive, organ sparing surgery avoiding the chances 
of thromboembolism, wound infection, faecal incontinence, 
impotence, chronic abdominal pain, hernias and adhesions 
that are all part of the package of classical open surgery.
Risk in endoscopy
So why do large numbers of patients continue to be treated 
surgically for benign polyps? The reasons for this are threefold. 
Firstly, perverse financial incentives. There are large financial 
disincentives to performing extensive endoscopic resections. 
Removing any polyp, whether 1 millimetre or 10 centimetres 
in diameter attracts the same fee while removing large polyps 
is many times more expensive, making it a loss making 
activity. Surgery for the same polyp attracts a much higher 
fee and is thus a much more profitable option for hospitals. 
Healthcare costs are driven up and patients suffer, but insurers 
and patients are not aware of this. Patients are usually very 
relieved to hear afterwards that the unnecessary operation was 
successful and that it wasn’t cancer after all but a benign polyp.
Secondly, logistical pressure on endoscopy capacity. Carefully 
removing a big polyp can take several times as long as a normal 
procedure. Its not easy to accurately estimate how long such 
a procedure will take and thus difficult to plan efficiently. The 
waiting lists and the sheer volume of colonoscopies arising 
from screening and a relative shortage of colonoscopists make 
it attractive to refer big polyps to the surgeon.
Thirdly, insufficient awareness and lack of data on relative 
risks. As physicians, colonoscopists are relatively risk averse. 
Colonoscopy was initially developed as a purely diagnostic 
tool. Therapy for bowel cancer and its precursors remained 
in the hands of the surgeons. However, increasingly the two 
once separate fields have come to overlap with endoscopic 
or surgical alternative approaches to the same problem. 
Colonoscopists have had to slowly acclimatise to the new 
potential for intervention and along with this acceptance of 
the accompanying risk of complications. This sometimes 
leads to risk avoidance strategies that ironically put the patient 
at more risk. Endoscopic removal of a large polyp is a high-
risk endoscopic procedure. Undertaking it will likely lead to 
a higher complication rate for the performing endoscopist 
and questions from colleagues and review boards. For many 
endoscopists fear of complications leads them to refer the 
patient for surgery and segmental bowel resection. On the 
surgical side of the fence the same problem looks entirely 
different. Compared to removing an advanced cancer it is a 
relatively simple procedure with a low complication rate. Any 
eventual complications will not be collected in a National 
Registry, as there is only a registry for operations for cancer. 
But these low surgical risks are still probably ten times 
higher than those of the ‘too risky’ endoscopic procedure. 
Unfortunately data collection is at present too poorly 
performed to allow accurate calculation and comparison of 
these two risks. So while we can be proud to have initiated 
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colon cancer screening programs throughout much of Europe, 
there is still scope for fine-tuning the treatment especially of 
large polyps.
This sharp division between surgical and endoscopic worlds, 
where you almost seem to have to step out of one to step 
into the other, may also be stifling advances in endoscopy. 
Endoscopic Submucosal Dissection, or ESD, is a relatively 
novel advanced endoscopic technique. Here polyps are 
removed meticulously in one piece and as comprehensively as 
possible without disturbing the muscle layer of the bowel. In 
Japan and other far eastern countries it has been embraced as 
being the ultimate in minimally invasive, organ sparing surgery 
offering improved pathological staging accuracy, reducing 
the need for secondary surgical resection and thus potentially 
reducing morbidity and mortality. From a surgical perspective 
ESD can be seen as cheap and safe surgery, and this seems to 
be how it is viewed in the Far East. But from an endoscopic 
perspective it is a complex, expensive and dangerous 
alternative to the simpler but messier Endoscopic Mucosal 
Resection, where the polyp is hacked away in chunks, and this 
seems to be how it is viewed in Europe. The two worlds of 
surgery and endoscopy should ideally blend into one with a 
smooth transition in procedural risk rather than the current 
stepwise disconnect.
So I hope we will gradually see endoscopic procedures 
to remove large polyps being treated more like surgical 
procedures. Concentration in expert centres will be formalised. 
Complications of both surgical and endoscopic resection 
of benign polyps will both be registered nationally. This 
together with individualised computer modelling of the 
risk of complications will allow direct comparison between 
surgical and endoscopic treatment options. Reimbursement 
will be independent of the technique used so that surgical or 
endoscopic removal of large polyps attracts the same fee and 
Gastroenterologists will feel equally personally responsible 
for the surgical risks they expose their patients to, as the 
endoscopic risks. 
Unfortunately as endoscopists we frequently stumble upon 
monsters where our current endoscopic arsenal has nothing 
to offer. The standard approach for invasive cancer, even when 
relatively small, is surgical resection. Nevertheless the last years 
have seen radical changes in approach specifically for rectal 
cancer. Strangely this has been simultaneously in two opposite 
directions. On the one hand surgery has progressed towards 
removal of increasing amounts of tissue leading to improved 
survival at the cost of increased morbidity, and on the other 
the rise of organ sparing minimally invasive approaches such 
as local radiotherapy. Increasing numbers of elderly patients 
with rectal cancer, suffering with other chronic diseases at the 
same time, form an ever-larger group in whom more extensive 
surgery will be unlikely to increase life expectancy and will be 
associated with an unacceptably high risk of complications. 
I believe that endoscopy will have an increasing role to play 
in minimally invasive cancer therapy as part of a combined 
approach, and advanced endoscopic imaging techniques will 
be increasingly employed for the assessment of response and 
follow up.
So endoscopy in colon cancer has a bright future with 
the prospect of an ever-expanding role in prevention and 
treatment with exciting developments in molecular imaging, 
tissue transplantation, and resection techniques.
And hast thou slain the Jabberwock? Well sadly not yet once 
and for all. Colon cancer remains a fearsome foe. But we are 
making inroads, with increasingly successful skirmishes aided 
by a succession of new looking glasses and at the current rate 
of progress it is not unthinkable that we will, one frabjous day, 
celebrate the taming if not the ultimate slaying of the monster.
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Wij bevinden ons aan het begin van een nieuw medisch tijdperk waar 
kanker doodsoorzaak nummer één wordt. De strijd tegen kanker 
wordt gevoerd met een snel uitbreidend arsenaal van middelen, maar 
vooruitgang staat of valt met het beter begrijpen van de ziekte. Ons 
begrip wordt gedreven door het ontwikkelen van nieuwe manieren om 
naar de ziekte te kijken; nieuwe ‘looking glasses’ zoals DNA sequencing 
technologie. Maar darmkanker leidt tot zulke chaotische veranderingen 
op moleculair niveau dat eenvoudige invalshoeken, zoals het bestuderen 
van erfelijke vormen van kanker, vaak meer bruikbare informatie leveren. 
Met vooruitgang in moleculair darmkankeronderzoek dreigt de kloof 
tussen de artsen en de onderzoekers zo groot te worden dat ze elkaar niet 
meer kunnen begrijpen. In het aanbrekende moleculaire tijdperk zullen 
clinici met moleculaire kennis steeds belangrijker zijn om deze kloof te 
overbruggen. De hoop blijft dat er, met meer kennis door ontwikkelingen 
van nieuwe moleculaire en endoscopische ‘looking glasses’, een tijd 
aanbreekt waar het monster darmkanker getemd zal worden.
